Dr. Reddy's Laboratories Limited RDY

Full chart Compare
Set alert

Price alert · RDY

All alert types
14.53 USD -0.24 (-1.62%)

At closeNov 5, 2026, 4:00 PM EST

14.53 0.00 0.00%

After hours · Nov 5, 4:00 PM ET

14.47 Day range 14.79
11.36 52-week range 15.67
YTD
+3.49%
1 year
+8.43%
Market cap
12.11B
Revenue (ttm)
329.84B
Profit margin
8.48%
EPS (ttm)
0.36
Shares out
833.07M
P/E ratio
40.36
Forward P/E
22.28
Dividend
0.08 (0.58%)
Ex-dividend date
Jul 8, 2026
YTD return
+3.49%
1-year return
+8.43%
Volume
4.81M
Avg volume
2.88M
Open
14.68
Previous close
14.77
Day's range
14.47 – 14.79
52-week range
11.36 – 15.67
Beta
0.20
Analysts
Buy
Price target
14.36 (-1.2%)
Earnings date
Jan 22, 2027

2Y -0.65 (-4.28%)

121416Nov 24Feb 25Apr 25Jun 25Aug 25Oct 25Dec 25Feb 26Apr 26Jun 26Aug 26Oct 2614.55

Key statistics

Enterprise value
70.57B
PEG ratio
1.98
Price / sales
0.04
Price / book
17.99
Dividend yield
0.58%
Payout ratio
22.72%
Revenue growth
-1.50%
Free cash flow
-6.59B
Total cash
76.24B
Total debt
72.29B
Return on equity
7.34%
Short % of float
3.81%
50-day average
12.62
200-day average
13.23

Financials — quick view

All financials
RDY Revenue — annual 335.93B
2011-FY 20112012-FY 20122013-FY 20132014-FY 20142015-FY 20152016-FY 20162017-FY 20172018-FY 20182019-FY 20192020-FY 20202021-FY 20212022-FY 20222023-FY 20232024-FY 20242025-FY 20252026-FY 2026
RDY Net income — annual 42.85B
2011-FY 20112012-FY 20122013-FY 20132014-FY 20142015-FY 20152016-FY 20162017-FY 20172018-FY 20182019-FY 20192020-FY 20202021-FY 20212022-FY 20222023-FY 20232024-FY 20242025-FY 20252026-FY 2026
RDY EPS — annual 51.48
2011-FY 20112012-FY 20122013-FY 20132014-FY 20142015-FY 20152016-FY 20162017-FY 20172018-FY 20182019-FY 20192020-FY 20202021-FY 20212022-FY 20222023-FY 20232024-FY 20242025-FY 20252026-FY 2026

Earnings

RDY recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Jan 22, 2027Dec 30, 20260.15———
Oct 23, 2026Sep 30, 20260.096790.12+0.02+23.98%
Jul 21, 2026Jun 30, 20260.091820.06-0.03-34.65%
May 11, 2026Mar 31, 20260.090.06-0.03-33.33%
Jan 20, 2026Dec 31, 20250.160.160.000.00%
Oct 24, 2025Sep 30, 20250.180.19+0.01+5.56%

Upgrades / downgrades

RDY analyst upgrades and downgrades
DateFirmActionFromTo
Sep 29, 2026CitigroupupSellBuy
Jun 5, 2025HSBCupHoldBuy
Nov 6, 2024BarclaysmainOverweightOverweight
Jul 30, 2024BarclaysmainOverweightOverweight
May 8, 2024BarclaysmainOverweightOverweight
Jan 29, 2024BarclaysmainOverweightOverweight

About Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
India
Website
drreddys.com

News

Your note

Sign in to keep a note on RDY — it syncs with the Stock Master app.

Institution ownership

RDY institution ownership
Holder% heldSharesValueReported
Morgan Stanley1.31%10,936,320161.47MJun 29, 2026
Blackrock Inc.1.27%10,585,742156.30MJun 29, 2026
Royal Bank of Canada1.10%9,213,269136.03MJun 29, 2026
Robeco Institutional Asset Management B.V.1.04%8,680,810128.17MSep 29, 2026
Aikya Investment Management Ltd1.02%8,493,852125.41MJun 29, 2026
Renaissance Technologies, LLC0.88%7,347,028108.48MJun 29, 2026

Fund ownership

RDY fund ownership
Holder% heldSharesValueReported
iShares, Inc.-iShares Core MSCI Emerging Markets ETF0.69%5,728,50784.58MSep 29, 2026
AB Active ETFs, Inc.-AB Emerging Markets Opportunities ETF0.45%3,744,21455.28MAug 30, 2026
College Retirement Equities Fd.-College Retirement Equities Fd. - Tota0.24%2,031,28129.99MJun 29, 2026
VANGUARD Intl Eqy. INDEX Fd.S-Vanguard Emerging Markets Stock Index Fd0.22%1,873,98027.67MJul 30, 2026
American Century ETF Trust-Avantis Emerging Markets Equity ETF0.22%1,811,31226.74MSep 29, 2026
SPDR INDEX SHARES Fd.S-State Street SPDR PORT. Emerging Markets ETF0.18%1,461,98721.59MSep 29, 2026